Last reviewed · How we verify
Remimazolam combined propofol
Remimazolam combined propofol, marketed by Sichuan Provincial People's Hospital, is a combination anesthetic currently available in the market. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market adoption.
At a glance
| Generic name | Remimazolam combined propofol |
|---|---|
| Sponsor | Sichuan Provincial People's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Combination of Remimazolam and Propofol During Drug-induced Sleep Endoscopy (PHASE4)
- Remimazolam for Bronchoscopy in High-Risk Patients (PHASE4)
- A Randomized, Controlled Clinical Trial Comparing Remimazolam Besylate Combined With Alfentanil Versus Propofol Combined With Alfentanil for Anesthesia in Thoracic Surgery (PHASE4)
- The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval: A Multicenter Randomized Controlled Trial. (NA)
- Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients (PHASE4)
- Perioperative GDNF as a Predictive Factor for Postoperative Delirium and Adverse Neurological Outcomes in Pediatric Surgery (NA)
- The Impact of Remimazolam Tosilate on Oxygenation and Postoperative Cognitive Function in Elderly Patients Undergoing Thoracoscopic Lobectomy (PHASE1, PHASE2)
- Comparison of Remimazolam and Propofol in Endoscopic Examinations and Treatments (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remimazolam combined propofol CI brief — competitive landscape report
- Remimazolam combined propofol updates RSS · CI watch RSS
- Sichuan Provincial People's Hospital portfolio CI